A detailed history of Geode Capital Management, LLC transactions in Equillium, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 216,204 shares of EQ stock, worth $296,199. This represents 0.0% of its overall portfolio holdings.

Number of Shares
216,204
Previous 199,728 8.25%
Holding current value
$296,199
Previous $461,000 67.68%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.66 - $2.33 $10,874 - $38,389
16,476 Added 8.25%
216,204 $149,000
Q1 2024

May 13, 2024

BUY
$0.73 - $3.0 $19,958 - $82,023
27,341 Added 15.86%
199,728 $461,000
Q3 2023

Nov 13, 2023

BUY
$0.72 - $0.9 $9,799 - $12,249
13,610 Added 8.57%
172,387 $127,000
Q4 2022

Feb 13, 2023

SELL
$0.83 - $2.26 $309 - $842
-373 Reduced 0.23%
158,777 $174,000
Q2 2022

Aug 12, 2022

BUY
$1.69 - $3.26 $3,258 - $6,285
1,928 Added 1.23%
159,150 $324,000
Q1 2022

May 13, 2022

BUY
$2.99 - $4.19 $9,080 - $12,725
3,037 Added 1.97%
157,222 $495,000
Q3 2021

Nov 12, 2021

BUY
$4.84 - $6.91 $17,438 - $24,896
3,603 Added 2.39%
154,185 $1.05 Million
Q2 2021

Aug 13, 2021

BUY
$5.11 - $7.64 $109,916 - $164,336
21,510 Added 16.67%
150,582 $886,000
Q1 2021

May 12, 2021

BUY
$5.03 - $10.5 $322,926 - $674,100
64,200 Added 98.96%
129,072 $922,000
Q4 2020

Feb 12, 2021

BUY
$3.48 - $6.58 $66,412 - $125,572
19,084 Added 41.68%
64,872 $347,000
Q3 2020

Nov 13, 2020

BUY
$2.78 - $26.5 $127,290 - $1.21 Million
45,788 New
45,788 $264,000
Q2 2019

Aug 14, 2019

SELL
$5.28 - $8.2 $105,700 - $164,155
-20,019 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$5.84 - $12.02 $14,080 - $28,980
2,411 Added 13.69%
20,019 $160,000
Q4 2018

Feb 13, 2019

BUY
$6.32 - $19.44 $111,282 - $342,299
17,608 New
17,608 $143,000

Others Institutions Holding EQ

About Equillium, Inc.


  • Ticker EQ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,352,100
  • Market Cap $47.1M
  • Description
  • Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...
More about EQ
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.